Which patients with resectable pancreatic cancer truly benefit from oncological resection: is it destiny or biology?

Pancreatic cancer has a dismal prognosis. A technically perfect surgical operation may still not provide a survival advantage for patients with technically resectable pancreatic cancer. Appropriate selection of patients for surgical resections is an imminent issue. Recent studies have provided an important clue on what serum biomarkers may be used to select out the patients who would unlikely benefit from the surgical resection.

• Publication year

  2015

• Venue

  Cancer Biology & Therapy

• Publication date

  2015-02-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/15384047.2014.1002699PMID 25714403PMCID PMC4622578
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A preoperative serum signature of CEA+/CA125+/CA19‐9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer

  2015cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• A Prospective Randomized Controlled Study Comparing Outcomes of Standard Resection and Extended Resection, Including Dissection of the Nerve Plexus and Various Lymph Nodes, in Patients With Pancreatic Head Cancer

  2014cited by this paper
• Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection

  2014cited by this paper
• Ligamentum teres hepatis patch enhances the healing of pancreatic fistula after distal pancreatectomy.

  2013cited by this paper
• Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

  2013cited by this paper
• Application of “Papillary-Like Main Pancreatic Duct Invaginated” Pancreaticojejunostomy for Normal Soft Pancreas Cases

  2013cited by this paper
• Pancreatic Ductal Adenocarcinoma: Is There a Survival Difference for R1 Resections Versus Locally Advanced Unresectable Tumors? What Is a “True” R0 Resection?

  2013cited by this paper
• CA125 is Superior to CA19-9 in Predicting the Resectability of Pancreatic Cancer

  2013cited by this paper
• Pancreatic stump-closed pancreaticojejunostomy can be performed safely in normal soft pancreas cases.

  2012cited by this paper
• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  2011cited by this paper
• Pancreatic cancer

  2011cited by this paper
• A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma.

  2005cited by this paper
• Cancer statistics

  1989cited by this paper

• Clinical Outcomes of Neoadjuvant Therapy Versus Upfront Surgery in Resectable Pancreatic Cancer: Systematic Review and Meta-analysis of Latest Randomized Controlled Trials

  2025cites this paper
• A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer

  2023cites this paper
• Bioinformatics Analysis of a Prognostic miRNA Signature and Potential Key Genes in Pancreatic Cancer

  2021cites this paper
• Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection

  2020cites this paper
• A new combined criterion to better predict malignant lesions in patients with pancreatic cystic neoplasms

  2018cites this paper
• Precision medicine in the treatment of pancreatic ductal adenocarcinoma

  2016cites this paper
• Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer

  2016cites this paper
• The crown jewelry of the surgeries for pancreatic cancer.

  2015cites this paper